236 related articles for article (PubMed ID: 34603199)
1. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.
Kan C; Zhang Y; Han F; Xu Q; Ye T; Hou N; Sun X
Front Endocrinol (Lausanne); 2021; 12():708494. PubMed ID: 34603199
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis.
Chen Y; Lv X; Lin S; Arshad M; Dai M
Front Endocrinol (Lausanne); 2022; 13():895458. PubMed ID: 35692410
[TBL] [Abstract][Full Text] [Related]
3. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.
Nguyen NN; Ho DS; Nguyen HS; Ho DKN; Li HY; Lin CY; Chiu HY; Chen YC
Metabolism; 2022 Jun; 131():155196. PubMed ID: 35367460
[TBL] [Abstract][Full Text] [Related]
4. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
5. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
6. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis.
Tian S; Jiang J; Wang J; Zhang Z; Miao Y; Ji X; Bi Y
Diabetes Metab Res Rev; 2023 Oct; 39(7):e3673. PubMed ID: 37302139
[TBL] [Abstract][Full Text] [Related]
7. Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis.
Han T; Ma S; Sun C; Zhang H; Qu G; Chen Y; Cheng C; Chen EL; Ayaz Ahmed M; Kim KY; Manem R; Chen M; Guo Z; Yang H; Yan Y; Zhou Q
Arch Med Res; 2022 Feb; 53(2):186-195. PubMed ID: 34412904
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
10. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study.
Losada E; Soldevila B; Ali MS; Martínez-Laguna D; Nogués X; Puig-Domingo M; Díez-Pérez A; Mauricio D; Prieto-Alhambra D
Osteoporos Int; 2018 Sep; 29(9):2079-2086. PubMed ID: 29860664
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
[TBL] [Abstract][Full Text] [Related]
12. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.
Madsen KS; Kähler P; Kähler LKA; Madsbad S; Gnesin F; Metzendorf MI; Richter B; Hemmingsen B
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012368. PubMed ID: 30998259
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
14. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus.
Li T; Providencia R; Mu N; Yin Y; Chen M; Wang Y; Liu M; Yu L; Gu C; Ma H
Cardiovasc Diabetol; 2021 Jan; 20(1):30. PubMed ID: 33516224
[TBL] [Abstract][Full Text] [Related]
15. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
Permana H; Audi Yanto T; Ivan Hariyanto T
Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
[TBL] [Abstract][Full Text] [Related]
16. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
17. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
18. Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs - The CAPISCO International Expert Panel.
Popovic DS; Papanas N; Koufakis T; Kotsa K; Mahmeed WA; Al-Rasadi K; Al-Alawi K; Banach M; Banerjee Y; Ceriello A; Cesur M; Cosentino F; Firenze A; Galia M; Goh SY; Janez A; Kalra S; Kempler P; Kapoor N; Lessan N; Lotufo P; Rizvi AA; Sahebkar A; Santos RD; Stoian AP; Toth PP; Viswanathan V; Rizzo M
Exp Clin Endocrinol Diabetes; 2023 May; 131(5):260-267. PubMed ID: 36693416
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
20. Metformin monotherapy for adults with type 2 diabetes mellitus.
Gnesin F; Thuesen ACB; Kähler LKA; Madsbad S; Hemmingsen B
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012906. PubMed ID: 32501595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
